Kenji Sakuma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kenji Sakuma has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Taro Kishi
Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
9 shared publications - Nakao Iwata
Fujita Health University
6 shared publications - Atsuhiko Ota
Department of Public Health, Fujita Health University, School of Medicine , Toyoake, Aichi
3 shared publications - Masaaki Matsunaga
Department of Public Health, Fujita Health University School of Medicine, Toyoake 470-1192, Japan
3 shared publications - Shinichi Tanihara
Department of Public Health, Kurume University School of Medicine, Kurume, Japan
3 shared publications - Yupeng He
Department of Public Health School of Medicine, Fujita Health University Toyoake Japan
3 shared publications
Latest Publications
- Open Access
- 10 October 2026
- Published by IMR Press in ALPHA PSYCHIATRY
- Vol. 27 (5)
Neuromodulation Therapies for Depression: Current Status and Future Directions
Major depressive disorder is a leading cause of disability worldwide, and many patients fail to achieve sustained remission with first-line pharmacotherapy or psychotherapy. This unmet need has traditionally been framed as treatment-resistant depression (TRD), defined by an inadequate response to antidepressant treatment. Within this context, neuromodulation has assumed an increasingly important role by providing mechanistically distinct interventions when medication-based approaches are insufficient, poorly tolerated, or too slow. In this expert opinion article, we present a targeted, clinically oriented review of two established neuromodulation therapies for depression, electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS), encompassing conventional repetitive TMS (rTMS), deep TMS, and theta-burst stimulation (TBS), as well as magnetic seizure therapy (MST), the most clinically advanced investigational convulsive modality. ECT remains the benchmark treatment for severe, urgent, psychotic, or otherwise refractory depression due to its rapid and robust efficacy, although its use is limited by anesthesia requirements, cognitive adverse effects, and associated stigma. TMS has the strongest evidence base among nonconvulsive neuromodulation treatments, with pivotal sham-controlled multicenter trials supporting conventional rTMS and deep TMS, while TBS protocols are improving feasibility, access, and scalability. MST is conceptually appealing as a more focal convulsive treatment designed to preserve antidepressant efficacy while reducing cognitive burden; recent Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST-MST) data have strengthened its evidence base, but its routine clinical role remains to be defined through regulatory approval, durability data, and implementation evidence. We argue that future progress will depend not only on the development of new stimulation protocols but also on improved clinical sequencing, patient selection, and maintenance strategies that help sustain acute gains. The concept of difficult-to-treat depression (DTD) broadens the clinical framework beyond antidepressant nonresponse to include persistent burden, partial response, tolerability constraints, functional impairment, and patient-centered goals. This perspective may inform earlier and more strategic use of neuromodulation, although most randomized controlled trials remain focused on TRD. Further studies are needed to determine whether DTD-based approaches improve real-world outcomes. Advances are likely to arise from integrating protocol refinement, individualized targeting, scalable home-based approaches, depression-relevant extensions such as bipolar depression, and durable maintenance strategies rather than identifying a single universally superior modality.
- 10 October 2026
- Published by IMR Press in ALPHA PSYCHIATRY
- Vol. 27 (5)
Open AccessNeuromodulation Therapies for Depression: Current Status and Future Directions
Major depressive disorder is a leading cause of disability worldwide, and many patients fail to achieve sustained remission with first-line pharmacotherapy or psychotherapy. This unmet need has traditionally been framed as treatment-resistant depression (TRD), defined by an inadequate response to antidepressant treatment. Within this context, neuromodulation has assumed an increasingly important role by providing mechanistically distinct interventions when medication-based approaches are insufficient, poorly tolerated, or too slow. In this expert opinion article, we present a targeted, clinically oriented review of two established neuromodulation therapies for depression, electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS), encompassing conventional repetitive TMS (rTMS), deep TMS, and theta-burst stimulation (TBS), as well as magnetic seizure therapy (MST), the most clinically advanced investigational convulsive modality. ECT remains the benchmark treatment for severe, urgent, psychotic, or otherwise refractory depression due to its rapid and robust efficacy, although its use is limited by anesthesia requirements, cognitive adverse effects, and associated stigma. TMS has the strongest evidence base among nonconvulsive neuromodulation treatments, with pivotal sham-controlled multicenter trials supporting conventional rTMS and deep TMS, while TBS protocols are improving feasibility, access, and scalability. MST is conceptually appealing as a more focal convulsive treatment designed to preserve antidepressant efficacy while reducing cognitive burden; recent Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST-MST) data have strengthened its evidence base, but its routine clinical role remains to be defined through regulatory approval, durability data, and implementation evidence. We argue that future progress will depend not only on the development of new stimulation protocols but also on improved clinical sequencing, patient selection, and maintenance strategies that help sustain acute gains. The concept of difficult-to-treat depression (DTD) broadens the clinical framework beyond antidepressant nonresponse to include persistent burden, partial response, tolerability constraints, functional impairment, and patient-centered goals. This perspective may inform earlier and more strategic use of neuromodulation, although most randomized controlled trials remain focused on TRD. Further studies are needed to determine whether DTD-based approaches improve real-world outcomes. Advances are likely to arise from integrating protocol refinement, individualized targeting, scalable home-based approaches, depression-relevant extensions such as bipolar depression, and durable maintenance strategies rather than identifying a single universally superior modality.
- 19 May 2026
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 276 (6) , 3061-3075
Efficacy and safety of Nrf2 activators for schizophrenia: a systematic review and meta-analysis
This systematic review and meta-analysis aimed to investigate the efficacy and safety of adding nuclear factor erythroid 2-related factor 2 (Nrf2) activators to antipsychotic treatments for individuals with schizophrenia. The primary outcome was overall symptom improvement. Other efficacy outcomes involve the improvement of positive symptoms, negative and depressive symptoms, Positive and Negative Syndrome Scale general subscale (PANSS-G) scores, and cognitive function composite scores and individual cognitive domain scores (only for sulforaphane). Further, we included all-cause discontinuation, adverse event-related discontinuation, incidence of individual adverse events, and changes in blood inflammatory biomarkers, lipid profiles, and glucose levels. Our review included 16 randomized-controlled trials (n = 953, mean age = 35.27 years; 66.74% male). Among these, 15 were placebo-controlled, while the remaining study did not utilize a placebo. This systematic review comprised six studies on ascorbic acid, four on curcumin, two on resveratrol, and four on sulforaphane. Curcumin showed marginal superiority over placebo for the primary outcome (standardized mean difference = - 0.53, 95% confidence interval: -1.08, 0.02); however, non-significant subgroup results (all p > 0.05) with wide confidence intervals across formulations and co-interventions suggest that these findings lack robustness. Curcumin significantly outperformed placebo in reducing positive symptoms, negative symptoms, and PANSS-G scores but did not differ from placebo for other outcomes. Sulforaphane showed a lower all-cause discontinuation rate than placebo, suggesting potential efficacy and better treatment adherence. Additionally, sulforaphane reduced total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels, though no significant differences were found in other outcomes. Meta-analysis of efficacy outcomes for ascorbic acid and resveratrol could not be conducted due to insufficient data.
- 19 May 2026
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 276 (6) , 3061-3075
Efficacy and safety of Nrf2 activators for schizophrenia: a systematic review and meta-analysis
This systematic review and meta-analysis aimed to investigate the efficacy and safety of adding nuclear factor erythroid 2-related factor 2 (Nrf2) activators to antipsychotic treatments for individuals with schizophrenia. The primary outcome was overall symptom improvement. Other efficacy outcomes involve the improvement of positive symptoms, negative and depressive symptoms, Positive and Negative Syndrome Scale general subscale (PANSS-G) scores, and cognitive function composite scores and individual cognitive domain scores (only for sulforaphane). Further, we included all-cause discontinuation, adverse event-related discontinuation, incidence of individual adverse events, and changes in blood inflammatory biomarkers, lipid profiles, and glucose levels. Our review included 16 randomized-controlled trials (n = 953, mean age = 35.27 years; 66.74% male). Among these, 15 were placebo-controlled, while the remaining study did not utilize a placebo. This systematic review comprised six studies on ascorbic acid, four on curcumin, two on resveratrol, and four on sulforaphane. Curcumin showed marginal superiority over placebo for the primary outcome (standardized mean difference = - 0.53, 95% confidence interval: -1.08, 0.02); however, non-significant subgroup results (all p > 0.05) with wide confidence intervals across formulations and co-interventions suggest that these findings lack robustness. Curcumin significantly outperformed placebo in reducing positive symptoms, negative symptoms, and PANSS-G scores but did not differ from placebo for other outcomes. Sulforaphane showed a lower all-cause discontinuation rate than placebo, suggesting potential efficacy and better treatment adherence. Additionally, sulforaphane reduced total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels, though no significant differences were found in other outcomes. Meta-analysis of efficacy outcomes for ascorbic acid and resveratrol could not be conducted due to insufficient data.
- 3 March 2026
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 197, 258-263
Acceptability of suvorexant versus lemborexant: An inverse probability of treatment weighting analysis
- 3 March 2026
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 197, 258-263
Acceptability of suvorexant versus lemborexant: An inverse probability of treatment weighting analysis
- Open Access
- 4 September 2025
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 45 (3) , e70045
Physical, Mental, and Social Characteristics Associated With Happiness in Individuals With Schizophrenia in Japan: A Cross‐Sectional Study
Objective: To examine the characteristics associated with happiness in Japanese individuals with schizophrenia. Methods: A self‐reported online survey was conducted in 2022 among individuals aged 20–75 years, including 223 and 1776 individuals with and without schizophrenia, respectively. We used a modified Poisson regression to assess the factors associated with happiness by calculating the age‐ and sex‐adjusted prevalence ratios (PRs). We examined within‐schizophrenia group differences by age and sex strata, and compared these stratified PRs between groups with and without schizophrenia. Results: Among participants with schizophrenia, happiness was significantly associated with self‐rated health status ( PR = 1.75), Ikigai ( PR = 5.02), depressive symptoms ( PR = 0.43), perceived stress ( PR = 0.52), cognitive social capital ( PR = 2.07), structural social capital ( PR = 1.70), social support ( PR = 2.40), close friends ( PR = 1.88), close relatives ( PR = 2.34), and a cohabiting partner ( PR = 1.57). Within the schizophrenia group, sex differences were significant for cognitive social capital (men: PR = 3.45; women: PR = 1.43) and cohabiting partners (men: PR = 2.26; women: PR = 1.25), whereas no significant age differences were found. Factors demonstrating a stronger association in participants with schizophrenia than in those without schizophrenia included: Ikigai (with, PR = 5.02; without, PR = 2.91), cognitive social capital (with, PR = 2.07; without, PR = 1.49), and structural social capital (with, PR = 1.70; without, PR = 1.24). Conclusion: Happiness in individuals with schizophrenia is associated with physical, mental, and social factors, with social factors exhibiting sex‐related differences.
- 4 September 2025
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 45 (3) , e70045
Open AccessPhysical, Mental, and Social Characteristics Associated With Happiness in Individuals With Schizophrenia in Japan: A Cross‐Sectional Study
Objective: To examine the characteristics associated with happiness in Japanese individuals with schizophrenia. Methods: A self‐reported online survey was conducted in 2022 among individuals aged 20–75 years, including 223 and 1776 individuals with and without schizophrenia, respectively. We used a modified Poisson regression to assess the factors associated with happiness by calculating the age‐ and sex‐adjusted prevalence ratios (PRs). We examined within‐schizophrenia group differences by age and sex strata, and compared these stratified PRs between groups with and without schizophrenia. Results: Among participants with schizophrenia, happiness was significantly associated with self‐rated health status ( PR = 1.75), Ikigai ( PR = 5.02), depressive symptoms ( PR = 0.43), perceived stress ( PR = 0.52), cognitive social capital ( PR = 2.07), structural social capital ( PR = 1.70), social support ( PR = 2.40), close friends ( PR = 1.88), close relatives ( PR = 2.34), and a cohabiting partner ( PR = 1.57). Within the schizophrenia group, sex differences were significant for cognitive social capital (men: PR = 3.45; women: PR = 1.43) and cohabiting partners (men: PR = 2.26; women: PR = 1.25), whereas no significant age differences were found. Factors demonstrating a stronger association in participants with schizophrenia than in those without schizophrenia included: Ikigai (with, PR = 5.02; without, PR = 2.91), cognitive social capital (with, PR = 2.07; without, PR = 1.49), and structural social capital (with, PR = 1.70; without, PR = 1.24). Conclusion: Happiness in individuals with schizophrenia is associated with physical, mental, and social factors, with social factors exhibiting sex‐related differences.
- Open Access
- 1 September 2025
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 21, 1935-1943
Efficacy and Safety of Phosphodiesterase-5 Inhibitors for Erectile Dysfunction in Schizophrenia: A Systematic Review and Meta-Analysis
Background: The benefits of phosphodiesterase-5 inhibitors in the treatment of sexual dysfunction and psychopathology of schizophrenia remain unclear. This systematic review and meta-analysis aimed to address the above clinical question. Methods: Our primary outcome includes erectile dysfunction (ED) assessed using standardized questionnaires. Other efficacy outcomes involve overall sexual dysfunction, overall schizophrenia symptoms, positive symptoms, and negative symptoms. Further, we included all-cause discontinuation, discontinuation due to adverse events, discontinuation due to consent withdrawal, headache, loss of appetite, and somnolence. A meta-analysis was conducted for outcomes if at least two studies in each drug group had sufficient data to conduct a meta-analysis for a specific outcome. Results: Our systematic review included five double-blind, randomized, placebo-controlled trials (n=155, mean age=37.18 years, male proportion=91.61%), consisting of one lodenafil, three sildenafil, and one tadalafil study. Among the three studies on sildenafil, only one reported outcomes on sexual dysfunction; however, it demonstrated that sildenafil improved ED in males with schizophrenia. Another study reported that sildenafil also outperformed placebo in terms of schizophrenia symptom improvement, especially negative symptoms. However, our meta-analysis revealed no significant differences in outcomes associated with psychopathology, all-cause discontinuation, discontinuation due to adverse events, discontinuation due to consent withdrawal, headache, loss of appetite, and somnolence between sildenafil and placebo. Tadalafil outperformed placebo in terms of ED improvement although this finding was derived from one study. Conclusion: Sildenafil and tadalafil may be treatment options for ED, although our meta-analysis of safety outcomes did not include tadalafil. Our meta-analysis revealed that sildenafil was well accepted and well tolerated, despite involving only two studies.
- 1 September 2025
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 21, 1935-1943
Open AccessEfficacy and Safety of Phosphodiesterase-5 Inhibitors for Erectile Dysfunction in Schizophrenia: A Systematic Review and Meta-Analysis
Background: The benefits of phosphodiesterase-5 inhibitors in the treatment of sexual dysfunction and psychopathology of schizophrenia remain unclear. This systematic review and meta-analysis aimed to address the above clinical question. Methods: Our primary outcome includes erectile dysfunction (ED) assessed using standardized questionnaires. Other efficacy outcomes involve overall sexual dysfunction, overall schizophrenia symptoms, positive symptoms, and negative symptoms. Further, we included all-cause discontinuation, discontinuation due to adverse events, discontinuation due to consent withdrawal, headache, loss of appetite, and somnolence. A meta-analysis was conducted for outcomes if at least two studies in each drug group had sufficient data to conduct a meta-analysis for a specific outcome. Results: Our systematic review included five double-blind, randomized, placebo-controlled trials (n=155, mean age=37.18 years, male proportion=91.61%), consisting of one lodenafil, three sildenafil, and one tadalafil study. Among the three studies on sildenafil, only one reported outcomes on sexual dysfunction; however, it demonstrated that sildenafil improved ED in males with schizophrenia. Another study reported that sildenafil also outperformed placebo in terms of schizophrenia symptom improvement, especially negative symptoms. However, our meta-analysis revealed no significant differences in outcomes associated with psychopathology, all-cause discontinuation, discontinuation due to adverse events, discontinuation due to consent withdrawal, headache, loss of appetite, and somnolence between sildenafil and placebo. Tadalafil outperformed placebo in terms of ED improvement although this finding was derived from one study. Conclusion: Sildenafil and tadalafil may be treatment options for ED, although our meta-analysis of safety outcomes did not include tadalafil. Our meta-analysis revealed that sildenafil was well accepted and well tolerated, despite involving only two studies.
- Open Access
- 26 June 2025
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 45 (3) , e70034
Efficacy and Safety of Histamine H3 Receptor Antagonist/Inverse Agonist Including Betahistine for Schizophrenia: A Systematic Review and Meta‐Analysis
Aim: Whether histamine H3 receptor antagonists (H3R‐ANTs)/inverse agonists (H3R‐IAs) provides benefit for the treatment of schizophrenia remains unclear. This meta‐analysis was conducted to address the above clinical question. Methods: Cognitive Function Scale's composite score (primary), seven domains of cognitive function (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning/problem solving, and social cognition) score, University of California San Diego Performance‐Based Skills Assessment score, psychopathology scales score, discontinuation rate, and incidence of individual adverse events were among the study outcomes. The standardized mean differences (SMD) or risk ratios (RR) with 95% confidence intervals (CIs) were calculated. Results: Our meta‐analysis included 11 double‐blind, randomized, placebo‐controlled trials ( n = 754). Our study evaluated ABT‐288, betahistine, betahistine+reboxetine, GSK239512, MK‐0249, and pitolisant. Betahistine has an H1‐receptor agonistic reaction and H3‐receptor antagonistic reaction, while other drugs only have an H3‐receptor antagonistic/inverse agonistic reaction. Hence, we conducted a meta‐analysis for all outcomes divided by betahistine or other pooled H3R‐ANTs/H3R‐IAs. The study results show that betahistine outperformed placebo in the improvement of overall cognitive symptoms (SMD [95% CI] = −0.61 [−1.03, −0.18]), speed of processing (−0.44 [−0.87, −0.02]), attention/vigilance (−0.43 [−0.85, −0.01]), working memory (−0.48 [−0.90, −0.06]), verbal learning (−0.62 [−1.04, −0.19]), visual learning (−0.57 [−1.00, −0.15]), and betahistine+reboxetine was superior in the improvement of depressive symptoms (−4.04 [−5.10, −2.97]). Pitolisant outperformed placebo in depressive symptom improvement (−3.24 [−4.22, −2.26]). However, the results were derived from one betahistine, betahistine+reboxetine, or pitolisant study. Other pooled H3R‐ANTs/H3R‐IAs revealed risk of insomnia (RR [95% CI] = 2.18 [1.05, 4.55]). However, no differences were observed in other any outcomes between betahistine or other pooled H3R‐ANTs/H3R‐IAs and placebo. Conclusions: Some H3R‐ANTs/H3R‐IAs might provide benefit for the treatment of cognitive symptoms and depressive symptoms in individuals afflicted with schizophrenia.
- 26 June 2025
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 45 (3) , e70034
Open AccessEfficacy and Safety of Histamine H3 Receptor Antagonist/Inverse Agonist Including Betahistine for Schizophrenia: A Systematic Review and Meta‐Analysis
Aim: Whether histamine H3 receptor antagonists (H3R‐ANTs)/inverse agonists (H3R‐IAs) provides benefit for the treatment of schizophrenia remains unclear. This meta‐analysis was conducted to address the above clinical question. Methods: Cognitive Function Scale's composite score (primary), seven domains of cognitive function (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning/problem solving, and social cognition) score, University of California San Diego Performance‐Based Skills Assessment score, psychopathology scales score, discontinuation rate, and incidence of individual adverse events were among the study outcomes. The standardized mean differences (SMD) or risk ratios (RR) with 95% confidence intervals (CIs) were calculated. Results: Our meta‐analysis included 11 double‐blind, randomized, placebo‐controlled trials ( n = 754). Our study evaluated ABT‐288, betahistine, betahistine+reboxetine, GSK239512, MK‐0249, and pitolisant. Betahistine has an H1‐receptor agonistic reaction and H3‐receptor antagonistic reaction, while other drugs only have an H3‐receptor antagonistic/inverse agonistic reaction. Hence, we conducted a meta‐analysis for all outcomes divided by betahistine or other pooled H3R‐ANTs/H3R‐IAs. The study results show that betahistine outperformed placebo in the improvement of overall cognitive symptoms (SMD [95% CI] = −0.61 [−1.03, −0.18]), speed of processing (−0.44 [−0.87, −0.02]), attention/vigilance (−0.43 [−0.85, −0.01]), working memory (−0.48 [−0.90, −0.06]), verbal learning (−0.62 [−1.04, −0.19]), visual learning (−0.57 [−1.00, −0.15]), and betahistine+reboxetine was superior in the improvement of depressive symptoms (−4.04 [−5.10, −2.97]). Pitolisant outperformed placebo in depressive symptom improvement (−3.24 [−4.22, −2.26]). However, the results were derived from one betahistine, betahistine+reboxetine, or pitolisant study. Other pooled H3R‐ANTs/H3R‐IAs revealed risk of insomnia (RR [95% CI] = 2.18 [1.05, 4.55]). However, no differences were observed in other any outcomes between betahistine or other pooled H3R‐ANTs/H3R‐IAs and placebo. Conclusions: Some H3R‐ANTs/H3R‐IAs might provide benefit for the treatment of cognitive symptoms and depressive symptoms in individuals afflicted with schizophrenia.
- Open Access
- 29 January 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e66330
Estimating the Prevalence of Schizophrenia in the General Population of Japan Using an Artificial Neural Network–Based Schizophrenia Classifier: Web-Based Cross-Sectional Survey
Background: Estimating the prevalence of schizophrenia in the general population remains a challenge worldwide, as well as in Japan. Few studies have estimated schizophrenia prevalence in the Japanese population and have often relied on reports from hospitals and self-reported physician diagnoses or typical schizophrenia symptoms. These approaches are likely to underestimate the true prevalence owing to stigma, poor insight, or lack of access to health care among respondents. To address these issues, we previously developed an artificial neural network (ANN)–based schizophrenia classification model (SZ classifier) using data from a large-scale Japanese web-based survey to enhance the comprehensiveness of schizophrenia case identification in the general population. In addition, we also plan to introduce a population-based survey to collect general information and sample participants matching the population’s demographic structure, thereby achieving a precise estimate of the prevalence of schizophrenia in Japan. Objective: This study aimed to estimate the prevalence of schizophrenia by applying the SZ classifier to random samples from the Japanese population. Methods: We randomly selected a sample of 750 participants where the age, sex, and regional distributions were similar to Japan’s demographic structure from a large-scale Japanese web-based survey. Demographic data, health-related backgrounds, physical comorbidities, psychiatric comorbidities, and social comorbidities were collected and applied to the SZ classifier, as this information was also used for developing the SZ classifier. The crude prevalence of schizophrenia was calculated through the proportion of positive cases detected by the SZ classifier. The crude estimate was further refined by excluding false-positive cases and including false-negative cases to determine the actual prevalence of schizophrenia. Results: Out of 750 participants, 62 were classified as schizophrenia cases by the SZ classifier, resulting in a crude prevalence of schizophrenia in the general population of Japan of 8.3% (95% CI 6.6%-10.1%). Among these 62 cases, 53 were presumed to be false positives, and 3 were presumed to be false negatives. After adjustment, the actual prevalence of schizophrenia in the general population was estimated to be 1.6% (95% CI 0.7%-2.5%). Conclusions: This estimated prevalence was slightly higher than that reported in previous studies, possibly due to a more comprehensive disease classification methodology or, conversely, model limitations. This study demonstrates the capability of an ANN-based model to improve the estimation of schizophrenia prevalence in the general population, offering a novel approach to public health analysis.
- 29 January 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e66330
Open AccessEstimating the Prevalence of Schizophrenia in the General Population of Japan Using an Artificial Neural Network–Based Schizophrenia Classifier: Web-Based Cross-Sectional Survey
Background: Estimating the prevalence of schizophrenia in the general population remains a challenge worldwide, as well as in Japan. Few studies have estimated schizophrenia prevalence in the Japanese population and have often relied on reports from hospitals and self-reported physician diagnoses or typical schizophrenia symptoms. These approaches are likely to underestimate the true prevalence owing to stigma, poor insight, or lack of access to health care among respondents. To address these issues, we previously developed an artificial neural network (ANN)–based schizophrenia classification model (SZ classifier) using data from a large-scale Japanese web-based survey to enhance the comprehensiveness of schizophrenia case identification in the general population. In addition, we also plan to introduce a population-based survey to collect general information and sample participants matching the population’s demographic structure, thereby achieving a precise estimate of the prevalence of schizophrenia in Japan. Objective: This study aimed to estimate the prevalence of schizophrenia by applying the SZ classifier to random samples from the Japanese population. Methods: We randomly selected a sample of 750 participants where the age, sex, and regional distributions were similar to Japan’s demographic structure from a large-scale Japanese web-based survey. Demographic data, health-related backgrounds, physical comorbidities, psychiatric comorbidities, and social comorbidities were collected and applied to the SZ classifier, as this information was also used for developing the SZ classifier. The crude prevalence of schizophrenia was calculated through the proportion of positive cases detected by the SZ classifier. The crude estimate was further refined by excluding false-positive cases and including false-negative cases to determine the actual prevalence of schizophrenia. Results: Out of 750 participants, 62 were classified as schizophrenia cases by the SZ classifier, resulting in a crude prevalence of schizophrenia in the general population of Japan of 8.3% (95% CI 6.6%-10.1%). Among these 62 cases, 53 were presumed to be false positives, and 3 were presumed to be false negatives. After adjustment, the actual prevalence of schizophrenia in the general population was estimated to be 1.6% (95% CI 0.7%-2.5%). Conclusions: This estimated prevalence was slightly higher than that reported in previous studies, possibly due to a more comprehensive disease classification methodology or, conversely, model limitations. This study demonstrates the capability of an ANN-based model to improve the estimation of schizophrenia prevalence in the general population, offering a novel approach to public health analysis.
- Open Access
- 17 May 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (10) , 2970
External Validation of a Machine Learning Model for Schizophrenia Classification
Background and Objective: Excellent generalizability is the precondition for the widespread practical implementation of machine learning models. In our previous study, we developed the schizophrenia classification model (SZ classifier) to identify potential schizophrenia patients in the Japanese population. The SZ classifier has exhibited impressive performance during internal validation. However, ensuring the robustness and generalizability of the SZ classifier requires external validation across independent sample sets. In this study, we aimed to present an external validation of the SZ classifier using outpatient data. Methods: The SZ classifier was trained by using online survey data, which incorporate demographic, health-related, and social comorbidity features. External validation was conducted using an outpatient sample set which is independent from the sample set during the model development phase. The model performance was assessed based on the sensitivity and misclassification rates for schizophrenia, bipolar disorder, and major depression patients. Results: The SZ classifier demonstrated a sensitivity of 0.75 when applied to schizophrenia patients. The misclassification rates were 59% and 55% for bipolar disorder and major depression patients, respectively. Conclusions: The SZ classifier currently encounters challenges in accurately determining the presence or absence of schizophrenia at the individual level. Prior to widespread practical implementation, enhancements are necessary to bolster the accuracy and diminish the misclassification rates. Despite the current limitations of the model, such as poor specificity for certain psychiatric disorders, there is potential for improvement if including multiple types of psychiatric disorders during model development.
- 17 May 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (10) , 2970
Open AccessExternal Validation of a Machine Learning Model for Schizophrenia Classification
Background and Objective: Excellent generalizability is the precondition for the widespread practical implementation of machine learning models. In our previous study, we developed the schizophrenia classification model (SZ classifier) to identify potential schizophrenia patients in the Japanese population. The SZ classifier has exhibited impressive performance during internal validation. However, ensuring the robustness and generalizability of the SZ classifier requires external validation across independent sample sets. In this study, we aimed to present an external validation of the SZ classifier using outpatient data. Methods: The SZ classifier was trained by using online survey data, which incorporate demographic, health-related, and social comorbidity features. External validation was conducted using an outpatient sample set which is independent from the sample set during the model development phase. The model performance was assessed based on the sensitivity and misclassification rates for schizophrenia, bipolar disorder, and major depression patients. Results: The SZ classifier demonstrated a sensitivity of 0.75 when applied to schizophrenia patients. The misclassification rates were 59% and 55% for bipolar disorder and major depression patients, respectively. Conclusions: The SZ classifier currently encounters challenges in accurately determining the presence or absence of schizophrenia at the individual level. Prior to widespread practical implementation, enhancements are necessary to bolster the accuracy and diminish the misclassification rates. Despite the current limitations of the model, such as poor specificity for certain psychiatric disorders, there is potential for improvement if including multiple types of psychiatric disorders during model development.
- Open Access
- 24 March 2021
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 51 (15) , 2730
Recurrence Rates in Stable Bipolar Disorder Patients after Drug Discontinuation versus Drug Maintenance: A Systematic Review and Meta-analysis – Corrigendum
- 24 March 2021
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 51 (15) , 2730
Open AccessRecurrence Rates in Stable Bipolar Disorder Patients after Drug Discontinuation versus Drug Maintenance: A Systematic Review and Meta-analysis – Corrigendum
- 1 March 2021
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 41 (2) , 204-206
The Efficacy and Safety of Lacosamide for Bipolar Depression
- 1 March 2021
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 41 (2) , 204-206
The Efficacy and Safety of Lacosamide for Bipolar Depression